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Advanced systemic mastocytosis (AdvSM) is a rare, KIT D816V-driven hematologic neoplasm characterized by mast cell infiltration and shortened survival. We report the results of a prespecified interim analysis of an ongoing pivotal single-arm phase 2
trial (no. NCT03580655) of avapritinib, a potent, selective KIT D816V inhibitor administered primarily at a once-daily starting dose of 200 mg in patients with AdvSM (n = 62). The primary endpoint was overall response rate (ORR). Secondary endpoints included mean baseline change in AdvSM–Symptom Assessment Form Total Symptom Score and quality of life, time
to response, duration of response, progression-free survival, overall survival, changes in measures of disease burden and
safety. The primary endpoint was successfully met (P = 1.6 × 10-9), with an ORR of 75% (95% confidence interval 57–89) in
32 response-evaluable patients with AdvSM who had sufficient follow-up for response assessment, including 19% with complete remission with full or partial hematologic recovery. Reductions of ≥50% from baseline in serum tryptase (93%), bone
marrow mast cells (88%) and KIT D816V variant allele fraction (60%) were observed. The most frequent grade ≥3 adverse
events were neutropenia (24%), thrombocytopenia (16%) and anemia (16%). Avapritinib demonstrated a high rate of clinical,
morphological and molecular responses and was generally well tolerated in patients with AdvSM.

S

ystemic mastocytosis (SM) is a rare hematologic neoplasm
that is associated with the KIT D816V mutation in ~95% of
cases. The KIT D816V mutation drives the increased proliferation and accumulation of neoplastic mast cells, leading to
severe, debilitating and often unpredictable symptoms and poor
quality of life (QoL)1–3. In AdvSM, mast cell infiltration leads to
organ damage, referred to as ‘C-findings’ (that is, cytopenias or
liver dysfunction), with limited treatment options and poor survival2,4–6. AdvSM is comprised of three subtypes: aggressive SM
(ASM), SM with an associated hematologic neoplasm (SM-AHN)
and mast cell leukemia (MCL)2. In SM-AHN, which represents
60–70% of cases of AdvSM7,8, patients concurrently have both SM
and another World Health Organization-defined hematologic neoplasm, usually myeloid (for example, myelodysplastic syndrome,

myeloproliferative neoplasm or an overlap)9. The KIT D816V mutation is frequently also present in cells comprising the AHN component9. Molecular subtyping of patients with AdvSM often reveals a
heterogenous genetic landscape, with high-risk mutations in splicing factors, epigenetic regulators and transcription factors such as
SRSF2, ASXL1 and RUNX1, respectively10–12. Treatment options
are very limited, with only the multikinase inhibitor midostaurin
and, more recently, the selective KIT kinase inhibitor avapritinib
approved for the treatment of AdvSM.
Avapritinib is a selective KIT and platelet-derived growth factor receptor-alpha (PDGFRA) kinase inhibitor with high potency
for the KIT D816V and homologous PDGFRA-mutant proteins1.
As detailed in the accompanying report13, avapritinib was investigated in patients with AdvSM in the phase 1 EXPLORER trial
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(no. NCT02561988)14. In this trial, avapritinib exhibited an ORR of
75% by modified (m)IWG–MRT–ECNM (International Working
Group–Myeloproliferative Neoplasms Research and Treatment
and European Competence Network) criteria, including 36% with
complete remission with full (CR) or partial hematologic recovery
(CRh), with a median follow-up of 23 months. Responses were seen
at all starting doses (30–400 mg once daily (QD)) and deepened
over subsequent cycles, but occurred most rapidly at 200 mg QD
and higher. Patients experienced profound reductions in objective
measures of mast cell burden, including complete molecular remission of KIT D816V, reversion of mast-cell-related organ damage
and improvements in symptoms. Review of safety, rapid reduction
of disease burden and response rate led to selection of 200 mg as the
optimal dose for patients with AdvSM.
Here, we present the results of a prespecified interim analysis
from the PATHFINDER trial15, an ongoing, international, multicenter, open-label, single-arm, phase 2 registrational trial (no.
NCT03580655) of avapritinib 200 mg QD in adult patients with a
centrally confirmed diagnosis of AdvSM. Patients were enrolled into
cohort 1 (efficacy evaluable) if they had an evaluable mIWG–MRT–
ECNM C-finding (that is, cytopenias, liver function abnormalities,
splenomegaly, ascites, pleural effusion) (Supplementary Table 1) at
baseline, or MCL irrespective of the presence of C-findings. The
primary endpoint of the trial was ORR, including CR/CRh, partial remission (PR) and clinical improvement (CI), as per mIWG–
MRT–ECNM criteria (Supplementary Table 2), which was tested
against 28%, the ORR of midostaurin, as per IWG–MRT–ECNM
criteria16. A prespecified interim analysis was performed when
32 patients in cohort 1 had sufficient follow-up for response evaluation (interim analysis efficacy population). In addition, cohort 2
included patients without an evaluable C-finding at baseline (that
is, evaluable C-findings that resolved with previous therapy or nonevaluable C-findings such as weight loss or large osteolytic lesions)
and were therefore not evaluable for response. All enrolled patients
(safety population) were included in secondary endpoints, which
included changes in patient symptoms, reduction in measures of
disease burden and safety.

Results

Participants. Between 21 November 2018 and 23 June 2020,
62 patients with prospectively centrally adjudicated AdvSM were
enrolled (ASM (n = 9), SM-AHN (n = 43) and MCL (n = 10)) and
received avapritinib primarily at a starting dose of 200 mg QD
(n = 60; two patients started at 100 mg QD), across cohort 1 (n = 52)
and cohort 2 (n = 10) (Extended Data Fig. 1). Avapritinib was
administered continuously in 28-day cycles until progression, intolerance, withdrawal by the investigator or patient or death.
The interim analysis was triggered when 32 response-evaluable
patients in cohort 1 achieved sufficient follow-up for confirmed
evaluation of response. The median age was 68 years (range, 37–85)
and 56% of patients were male (Table 1). By central assessment,
94% were positive for the KIT D816V mutation and 53% carried
an additional mutation in at least one of the genes SRSF2, ASXL1
or RUNX1 (S/A/R), which is associated with poor survival in SM12.
The majority of patients (72%) had received previous antineoplastic therapy, including 53% with midostaurin (Extended Data Fig.
2). Baseline median bone marrow mast cell percentage was 50%
(range, 10–95) and median serum tryptase was 293 ng ml–1 (range,
24–1,600). The median KIT D816V variant allele fraction (VAF)
in peripheral blood (which rarely has circulating mast cells) was
15% (range, 0–45). Median spleen volume was 939 ml (range, 150–
2,270). Baseline characteristics were generally balanced between
the safety population and those included versus not included in the
interim analysis efficacy population (Extended Data Fig. 3). In the
interim analysis efficacy population, the most common baseline
eligible mIWG–MRT–ECNM C-findings (Supplementary Table 1)

Table 1 | Baseline characteristics
Safety population
(n = 62)

Interim analysis
efficacy population
(n = 32)

Median age, years
(range)

69 (31–88)

68 (37–85)

Male/female, n (%)

34 (55)/28 (45)

18 (56)/14 (44)

ECOG performance status, n (%)
0–1

43 (69)

21 (66)

2–3

19 (31)

11 (34)

AdvSM subtype as per central assessment, n (%)
ASM

9 (15)

2 (6)

SM-AHN

43 (69)

26 (81)

MCL

10 (16)

4 (13)

KIT D816V mutation status in peripheral blood by central ddPCR, n (%)
Positive

59 (95)

Negative

3 (5)

KIT D816V variant
allele fraction in blood,
median percentage
(range)

18 (0–47)

30 (94)
2 (6)
15 (0–45)

SRSF2/ASXL1/RUNX1 mutation as per central assay, n (%)
Positive

26 (42)

17 (53)

Negative

36 (58)

15 (47)

Previous antineoplastic therapy, n (%)
Any

42 (68)

23 (72)

Midostaurin

34 (55)

17 (53)

Cladribine

8 (13)

4 (13)

Imatinib

5 (8)

4 (13)

Interferon
Bone marrow biopsy
mast cell burden
median percentage
(range)

6 (10)
45 (1–95)

2 (6)
50 (10–95)

Serum tryptase level,
median ng ml–1 (range)

283 (24–1,600)

293 (24–1,600)

Spleen volume, median
ml (range)

748 (44–2,601)

939 (150–2,270)

ddPCR, droplet digital PCR.

were splenomegaly (44%), elevated alkaline phosphatase (41%) and
transfusion-independent anemia (41%) (Extended Data Fig. 4).
Interim analysis of efficacy. Among 32 patients in the interim
analysis efficacy population (median follow-up of 10.4 months),
the confirmed ORR (CR/CRh/PR/CI; primary endpoint) was 75%
(n = 24, 95% confidence interval, 57–89, P = 1.6 × 10-9), with six
patients (19%) achieving CRh. Ten patients (31%) achieved PR
and eight (25%) had CI (Table 2). Responses were observed in all
AdvSM subtypes, regardless of exposure to previous therapy (Table
2). Additionally, ORR was similar among patients with (71% (95%
confidence interval, 44–90), 12/17) and without (80% (95% confidence interval, 52–96), 12/15) baseline S/A/R mutations. Responses
were rapid, with a median time to response of 2 months (range,
0.3–12.2). Responses continued to improve over time (Fig. 1), with
a median time to CRh of 5.6 months (range, 1.8–6.1).
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Table 2 | Response rates by adjudicated mIWG–MRT–ECNM response criteria
Best confirmed response,
n (%)

All AdvSM
(n = 32)

ORR (CR + CRh + PR + Cl)
95% Confidence interval

AdvSM subtype

Previous therapy

Previous midostaurin

ASM
(n = 2)

SM-AHN
(n = 26)

MCL
(n = 4)

Yes
(n = 23)

No
(n = 9)

Yes
(n = 17)

No
(n = 15)

24 (75)

2 (100)

21 (81)

1 (25)

17 (74)

7 (78)

14 (82)

10 (67)

57–89

16–100

61–93

1–81

52–90

40–97

57–96

38–88

CR or CRh

6 (19)

1 (50)

5 (19)

0

3 (13)

3 (33)

3 (18)

3 (20)

CR

0

0

0

0

0

0

0

0

CRh

6 (19)

1 (50)

5 (19)

0

3 (13)

3 (33)

3 (18)

3 (20)

PR

10 (31)

1 (50)

8 (31)

1 (25)

7 (30)

3 (33)

5 (29)

5 (33)

CI

8 (25)

0

8 (31)

0

7 (30)

1 (11)

6 (35)

2 (13)

Stable disease

4 (13)

0

2 (8)

2 (50)

2 (9)

2 (22)

0

4 (27)

Progressive disease

1 (3)

0

0

1 (25)

1 (4)

0

0

1 (7)

Not evaluable

3 (9)a

0

3 (12)

0

3 (13)

0

3 (18)

0

Best response

Three (9%) patients were in the interim analysis efficacy population but were assessed as not evaluable for response due to coming off trial before a confirmed response could be determined (13 weeks).

a

Starting
Diagnosis dose (mg)
SM-AHN
SM-AHN
SM-AHN
MCL
SM-AHN
SM-AHN
SM-AHN
ASM
SM-AHN
SM-AHN
MCL
SM-AHN
SM-AHN
SM-AHN
SM-AHN
ASM
SM-AHN
SM-AHN
SM-AHN
SM-AHN
SM-AHN
SM-AHN
SM-AHN
SM-AHN
SM-AHN
SM-AHN
SM-AHN
MCL
MCL
SM-AHN
SM-AHN
SM-AHN

200
200
200
200
200
200
200
200
100
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
200
Cycle
Study day

Best
response
PR
CRh
CRh
PR
CI
CRh
PR
PR
CI
CRh
SD
PR
PR
CI
CI
CRh
CI
PR
CI
CRh
CI
PR
SD
PR
PR
CI
SD
SD
PD
NE
NE
NE
C1
D1

Treatment ongoing
CRh

C3
D57

C7
D169

C11
D281

PR

CI

SD

C18
D477

PD

NE

C24
D645

Fig. 1 | Adjudicated mIWG–MRT–ECNM response by cycle. Includes patients in the interim analysis efficacy population (n = 32). SD, stable disease; PD,
progressive disease; NE, not evaluable.

In the safety population (n = 62), consistent and profound reductions in measures of mast cell burden (secondary endpoint) were
observed in all enrolled patients with baseline and postbaseline
assessments. A reduction of ≥50% in bone marrow mast cells was
2194

observed in 88% (44/50) of patients, and 60% (30/50) had elimination
of bone marrow mast cell aggregates (Fig. 2a). The serum tryptase
level decreased by ≥50% in 93% (54/58) of patients, and 43% (25/58)
of patients achieved serum tryptase levels <20 ng ml–1 (Fig. 2b).
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–80
–100
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Serum tryptase <20 ng ml–1
A: ASM, H: SM-AHN, M: MCL

Maximum percentage change
from baseline

c

20
0
–20
–40
–60
–80
–100

H H H H H H H H H H A H H H H H H H H H H H A M A H H A H HMMH HMMHMMMH H H A H H H H A H H A H HM
KIT D816V VAF <1%
A: ASM, H: SM-AHN, M: MCL

Maximum percentage change
from baseline

d

60
40
20
0
–20
–40
–60
–80
–100

H H A H H H H H H H H M H H H H H H A H A H H H H M H M A A H H H H A A H H H M H M M H H H H
A: ASM, H: SM-AHN, M: MCL

Fig. 2 | Change from baseline in clinicopathological measures of response. a, Bone marrow mast cells. b, Serum tryptase. c, KIT D816V variant allele
fraction. d, Spleen volume. MC, mast cell.

Nature Medicine | VOL 27 | December 2021 | 2192–2199 | www.nature.com/naturemedicine

2195

Articles

Nature Medicine

Table 3 | Adverse events (safety population, n = 62)
Any-cause AEs

Treatment-related AEs

Any grade

Grade ≥3

Any grade

Grade ≥3

62 (100)

42 (68)

57 (92)

32 (52)

Peripheral edema

31 (50)

2 (3)

26 (42)

1 (2)

Periorbital edemab

30 (48)

2 (3)

28 (45)

2 (3)

Any AE, n (%)
Nonhematologic AEsa, n (%)

Diarrhea

14 (23)

1 (2)

7 (11)

1 (2)

Nausea

11 (18)

1 (2)

5 (8)

0

Vomiting

11 (18)

1 (2)

6 (10)

1 (2)

Fatigue

9 (15)

2 (3)

6 (10)

2 (3)

Increased blood alkaline phosphatase

7 (11)

3 (5)

2 (3)

1 (2)

Thrombocytopeniab

28 (45)

10 (16)

25 (40)

9 (15)

Anemiab

20 (32)

10 (16)

12 (19)

5 (8)

Neutropeniab

15 (24)

15 (24)c

14 (23)

14 (23)c

Leukopenia

7 (11)

3 (5)

7 (11)

3 (5)

7 (11)

0

–

–

Hematologic AEsa, n (%)

b

AEs of special interest, n (%)
Cognitive effects
Confusional state

3 (5)

0

–

–

Memory impairment

3 (5)

0

–

–

Cognitive disorder

2 (3)

0

Intracranial bleeding
Subdural hematoma

–

–

1 (2)

1 (2)

d

–

–

1 (2)

1 (2)d

–

–

Any-cause AEs in ≥15% (any grade) or ≥5% (grade ≥3) of patients are listed. bPooled terms. cGrade 4 neutropenia of any cause and treatment-related occurred in 5 (8%) and 4 (6%) patients,
respectively. dGrade 4 event that occurred before risk mitigation measures were implemented.

a

Profound reductions in disease activity beyond mast cells were
also observed, with a decrease of ≥50% in absolute monocyte
counts in 80% (16/20) of patients with SM and chronic myelomonocytic leukemia (SM-CMML), and a decrease of ≥50% in absolute
eosinophil counts in 88% (14/16) of patients with eosinophilia,
including all three patients with SM and chronic eosinophilic leukemia (SM-CEL) (Extended Data Fig. 5). Consistent with efficacy
against KIT D816V mutant-bearing cells, there was a substantial
(≥50%) reduction in KIT D816V VAF in the peripheral blood in
60% (33/55) of patients; 35% (19/55) of patients achieved a VAF of
<1% (Fig. 2c). Spleen volume, which may be greatly enlarged due to
involvement by both neoplastic mast cells and AHN, was reduced
from baseline by ≥35% in 66% (31/47) of patients (Fig. 2d).
The majority of mIWG–MRT–ECNM C-findings in patients in the
interim analysis efficacy population resolved from baseline, including 83% of pleural effusions, 79% of splenomegaly and 57% of ascites (Extended Data Fig. 4). Resolution of cytopenia was less frequent,
despite elimination of bone marrow mast cell aggregates in the majority of patients, consistent with additional etiologies for cytopenia, such
as persistent AHN and/or avapritinib-related myelosuppression.
Median progression-free survival (PFS) in the interim analysis
efficacy population and median overall survival (OS) in the safety
population (secondary endpoints) had not been reached at the time
of data cutoff. The estimated 6-, 9- and 12-month PFS rates were
91, 87 and 79%, respectively; corresponding OS rates were 94, 86
and 86%.
Safety. As of the data cutoff, 52 (84%) of 62 patients were still on
treatment with a median follow-up of 7.0 months (range 5.6–8.1).
Reasons for treatment discontinuation included adverse events
2196

(AEs) in six patients (with three considered treatment-related
according to the local site investigator (decreased weight, subdural hematoma and bleeding propensity with subcutaneous hematoma)), disease progression as per the investigator in three patients
(with one transformation to acute myeloid leukemia and two with
worsening AHN) and consent withdrawal in one patient (Extended
Data Fig. 1).
The most frequent AEs are presented in Table 3. The most frequent nonhematologic AEs (any grade; grade ≥3) were peripheral
edema (50%; 3%), periorbital edema (48%; 3%), diarrhea (23%; 2%),
nausea (18%; 2%) and vomiting (18%; 2%). The most frequent hematologic AEs (any grade; grade ≥3) were thrombocytopenia (45%;
16%), anemia (32%; 16%) and neutropenia (24%; 24%), although
grade 4 neutropenia (absolute neutrophil count <0.5 × 109 l–1) was
uncommon, at 8%. Grade ≥3 treatment-related AEs were reported
in 32 (52%) patients, the most frequent of which were neutropenia
(23%) and thrombocytopenia (15%). There were three (5%) deaths
due to AEs (disease progression, necrotizing fasciitis and hemorrhagic shock), none of which were considered related to treatment.
Cognitive effects (confusional state, memory impairment and cognitive disorder) occurred in seven (11%) patients (Table 3) and were
primarily grade 1 (n = 6), with one grade 2.
There was one (1.6%) intracranial bleeding (ICB) event (subdural hemorrhage), in a patient with severe thrombocytopenia at
baseline (platelets, 49 × 109 l–1) who was enrolled before the exclusion (below) of such patients. The patient was treated with avapritinib despite worsening thrombocytopenia (platelets, 33 × 109 l–1)
and developed a grade 2 subdural hematoma 2 days after a single
dose of enoxaparin. The patient was not taking antiplatelet agents
and had a relatively normal international normalized ratio and
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95% CI
Mean BL
score:
37.8

40

C11
32.4

C3
18.2

30
20
10
0
Cycle
n

BL
54

1.5
46

2
46

3
43

5
26

7
24

9
18

90
80
70

C11

60

C3

50
40
30

BL

20
10
0

11
9

QoL

50

100
Mean EORTC–QLQ–C30 score

60

Improvement in QoL

Mean change from baseline
EORTC–QLQ–C30 global health score

b

Vomiting

70

0

Social
functioning

95% CI

1

Fatigue

−16

2

Cognitive
functioning

−14

Mean BL
score:
18.3

Emotional
functioning

−12

Diarrhea

−10

3

Nausea

−8

C3

Flushing

C11
–9.8 (P < 0.001)

C11

Role
functioning

−6

4

Itching

C3
–7.1

5

Physical
functioning

−4

BL

Spots

−2

6

Abdominal
pain

56 53 51 49 45 41 36 35 28 24 22
BL 2 3 4 5 6 7 8 9 10 11
Mean AdvSM–SAF symptom score

n
Cycle
0

Reduction in symptoms

Mean change from baseline
AdvSM–SAF TSS

a

Fig. 3 | Patient-reported outcomes. a, AdvSM–SAF TSS. b, EORTC–QLQ–C30 global health score. BL, baseline. C, cycle.

activated partial thromboplastin time of 1.2 and 28.1 s, respectively,
before the ICB event. The patient subsequently recovered from the
event and was retreated with avapritinib due to continuing benefit.
However, the patient subsequently developed a grade 4 subdural
hematoma despite platelets being 167 × 109 l–1, leading to treatment
discontinuation.
Safety analysis of this event and similar ICB events in the concurrent phase 1 trial identified patients with baseline severe thrombocytopenia at substantially increased risk of ICB; therefore, patients
with platelets <50 × 109 l–1 at baseline were subsequently excluded
from enrollment in both studies. In addition, the studies were
amended to include increased platelet count monitoring, updated
dose guidance for interruption, support for severely low platelet
counts and treatment discontinuation for any grade of ICB events.
In total, six patients (10%) experienced AEs leading to permanent treatment discontinuation. Two (5%) patients discontinued
due to a treatment-related serious AE (subdural hematoma and
bleeding propensity with subcutaneous hematoma). Dose interruptions due to AEs occurred in 34 (55%) patients, most commonly
due to neutropenia (21%) and thrombocytopenia (16%) (Extended
Data Fig. 6). AEs led to dose reductions in 42 (68%) patients, most
commonly due to neutropenia (19%) and thrombocytopenia (18%).
The median time to dose reduction was 7.4 weeks, and most patients
were taking a daily dose of 100 mg after cycle 3. The median daily
dose was 138 mg (range, 38–240), consistent between patients with
or without before exposure to therapy or midostaurin.
Patient-reported outcomes and QoL. Patients’ baseline QoL was
negatively impacted by their disease, with a pretreatment mean

European Organization for Research and Treatment of Cancer Core
QoL Questionnaire C30 (EORTC–QLQ–C30–QoL) score of only
37.8 (range, 0–100, where 0 represents the lowest QoL and 100 the
highest) and a high proportion of patients (31%) with a poor Eastern
Cooperative Oncology Group (ECOG) performance status of 2 or 3.
Mean and median Patient Global impression of Symptom Severity
(PGIS) scores were 2.6 and 3.0, respectively (where 0 represents no
symptoms and 4 very severe symptoms). The AdvSM–Symptom
Assessment Form (SAF), an AdvSM-specific patient reported outcomes tool, showed that fatigue, abdominal pain and spots were the
most severe symptoms, with a mean total symptom score (TSS) of
18.3, which was the sum of eight possible common symptoms (each
scored 0–10, where 0 represents no symptoms and 10 is the worst
imaginable). At baseline, patients had frequent supportive care
medication use, including H1 antihistamines (58%), H2 antihistamines (39%) and corticosteroids (32%). Patients on corticosteroids
remained evaluable if their dose did not exceed 20 mg d–1 of prednisone or equivalent.
Patient-reported symptoms, as measured by TSS score, improved
rapidly following treatment initiation, dropping by 7.1 points from
baseline at cycle 3 (n = 51) and by 9.8 points from baseline at treatment cycle 11 (n = 22; P < 0.001) (secondary endpoint; Fig. 3a).
Mean symptom scores were lower than baseline at cycles 3 and 11
for all SM symptoms, including fatigue, abdominal pain, spots, itching, flushing, nausea, diarrhea and vomiting. Mean and median
PGIS scores improved to 1.6 and 2.0 (moderate symptoms that
are difficult to ignore), respectively, by cycle 3 and to 1.2 and 1.0
(minimal symptoms that are easy to ignore), respectively, by cycle 11
(secondary endpoint).
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Quality of life, as assessed by EORTC–QLQ–C30, improved on
trial with noteworthy improvements in physical (strenuous activity), role (work or household jobs), emotional (irritability, feeling
tense and depression), cognitive (memory and concentration) and
social (family life and social activities) functioning domains (secondary endpoint; Fig. 3b).

Discussion

This prespecified interim analysis of the phase 2 PATHFINDER
trial demonstrated that avapritinib at a starting dose of 200 mg QD
exhibited clinical benefit in patients with AdvSM, confirming findings from the phase 1 EXPLORER trial. In total, 75% of patients
achieved a response regardless of AdvSM subtype, previous therapy
or adverse S/A/R comutations, with a rapid median time to response
of 2 months. With median follow-up of 10.4 months, 19% of patients
had normalized all baseline evaluable C-findings, eliminated mast
cell aggregates and reduced tryptase to <20 ng ml–1, to achieve
CRh. In June 2021, data from this and the phase 1 EXPLORER
trial (no. NCT02561988) formed the basis of approval by the
United States Food and Drug Administration for the treatment
of adults with AdvSM at a recommended starting dose of 200 mg
orally QD.
Consistent and profound reductions in mast cell burden
(bone marrow mast cells, serum tryptase) and normalization of
SM-related organ damage (that is, liver function abnormalities,
ascites, spleen size) were observed in patients across all AdvSM
subtypes regardless of previous therapy. Although improvements
in cytopenias were seen in some patients, including improvement
of transfusion-dependent anemia in one patient, cytopenias were
less likely to normalize than other C-findings, even in patients who
no longer had bone marrow mast cell aggregates. This implies that
persistent cytopenias were related to non-mast cell causes, such as
drug effect and/or the remaining AHN component.
In addition, avapritinib demonstrated evidence of broader
disease activity in patients with SM-AHN, which comprises the
majority of AdvSM variants. For example, substantial reductions
of monocytosis in 80% of patients with SM-CMML and eosinophilia in 88% patients with baseline eosinophilia or SM-CEL were
observed. Overall, 60% of patients had substantial reductions in
peripheral blood KIT D816V VAF, consistent with broad activity
against both KIT D816V-positive mast cells (which rarely circulate
in the blood) and cells derived from the AHN which often harbor
KIT D816V, reflecting multilineage involvement of the mutation.
Some patients with SM-AHN may need AHN therapy in combination or in sequence with a KIT-inhibitor-based regimen to address
the genetic and biologic heterogeneity which underpins this AdvSM
subtype. However, most patients had improvement in their AHN
with avapritinib alone. This activity supports exploration of avapritinib in other KIT D816V-positive hematologic malignancies.
Patients had marked impairments in QoL at baseline due to
their AdvSM symptoms yet reported rapid, durable and substantial
reductions from baseline in every AdvSM symptom assessed, and
improvements in QoL and functional impairment. Median global
symptom severity as measured by PGIS had improved from severe
to minimal by cycle 11.
Avapritinib was generally well tolerated, with few discontinuations due to AEs. Overall, the safety profile at the starting dose of
200 mg QD in the PATHFINDER trial included mostly low-grade
fluid retention and gastrointestinal symptoms as the most common
nonhematologic AEs. Cytopenias were the most common grade ≥3
AEs and reason for dose reduction, most commonly in patients with
baseline cytopenias, and 100 mg was the median daily dose after
cycle 3. Cognitive effects, which are dose-related, were relatively
uncommon at a starting dose of 200 mg.
The incidence of ICB was low (1.6%), and similar to that observed
with avapritinib in patients with GIST17,18, probably due to mitigation
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steps for severe thrombocytopenia which were implemented early
in enrollment. These included exclusion of patients with platelets
<50 × 109 l–1, closer monitoring of platelet counts, stricter dose
modification guidelines and use of platelet transfusions and growth
factors to maintain platelet count to ≥50 × 109 l–1. Dose-related,
low-grade cognitive events were observed but did not result in substantial dose reductions. The optimal starting dose of 200 mg QD
was confirmed in the current trial, because preliminary data generated in the EXPLORER trial suggested that this dose maintained
efficacy while improving tolerability.
These data reinforce KIT D816V as a clinically validated drug
target in AdvSM. While the multikinase inhibitor midostaurin is
already approved for use in patients with AdvSM, there remains a
substantial need for improvement in the overall rate, durability and
quality of responses19–22. Treatment with midostaurin for AdvSM
can lead to challenging gastrointestinal side effects, limiting its efficacy. With avapritinib, a potent, selective inhibitor of KIT D816V,
the clinical aim in AdvSM is to achieve deeper and enduring clinical, morphological and molecular responses, which could translate
into extended survival with improved QoL.
A potential limitation of this prespecified interim analysis is
the short duration of follow-up (10.4 months) in a subset of trial
patients, which will be addressed in long-term follow-up analyses of
the study. It is anticipated that findings from long-term analyses will
be consistent with those observed in the phase 1 trial13.
In conclusion, interim results from the current phase 2
PATHFINDER trial corroborate the promising and durable outcomes
observed in the phase 1 EXPLORER trial. Avapritinib administered at
a starting dose of 200 mg QD was well tolerated and led to profound
reductions in disease burden, improved patient symptoms and QoL,
and elicited deep molecular responses of KIT D816V, highlighting the
potential for modification of AdvSM disease natural history.
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Participants. Eligible patients were ≥18 years of age and with a diagnosis of
AdvSM confirmed by central review. The primary efficacy endpoint of ORR as
per mIWG–MRT–ECNM criteria23 required an evaluable baseline C-finding
(Supplementary Table 1), and these patients were enrolled into cohort 1. Patients
who did not have an evaluable C-finding at baseline could not be assessed for
the primary endpoint and were enrolled into cohort 2, with the exception of
patients with MCL who, as per criteria, were enrolled in cohort 1 and evaluated for
reductions in disease burden. As a result of emerging evidence that an increased
risk of ICB is associated with grade 3 thrombocytopenia, the protocol was amended
to exclude patients with baseline platelet count <50 × 109 l–1.
Additional inclusion criteria were as follows: patients with SM-AHN who
had received previous treatment for the AHN component of disease if, in the
opinion of the investigator, such therapy was appropriate; bone marrow biopsy
taken within 56 days of cycle 1, day 1 (C1D1); serum tryptase levels ≥20 ng ml–1;
ECOG performance status 0–3; discontinued cytoreductive therapy due to disease
progression, refractory disease, lack of efficacy or intolerance if receiving therapy
within the preceding 12 weeks; stable dose of nonantineoplastic SM therapies or
corticosteroids (≤20 mg d–1 prednisone or equivalent) for ≥14 days before C1D8;
and able to provide written informed consent. Patients were excluded for the
following reasons: received previous treatment with avapritinib; received any
cytoreductive therapy or an investigational agent <14 days and, for cladribine,
interferon alpha, pegylated interferon and any antibody therapy, <28 days before
obtaining screening bone marrow biopsy; received previous radiotherapy or any
hematopoietic growth factor within 14 days before screening bone marrow biopsy;
requires concomitant medication that is a strong inhibitor, strong inducer or
moderate inducer of cytochrome P450 3A4; had a major surgical procedure within
14 days of the first dose of study drug; is a candidate for allogeneic hematopoietic
stem cell transplantation for treatment of SM; eosinophilia and known positivity
for the FIP1L1–PGDFRA fusion, unless the patient has demonstrated relapse or
progressive disease on previous imatinib therapy; has history of another primary
malignancy (within 3 years before the first dose of study drug), cerebrovascular
accident or transient ischemic attacks (within 1 year before the first dose of
study drug), or seizure disorder; has abnormal laboratory findings or QT
interval corrected using Fridericia’s formula >480 ms; has known risk or recent
history of ICB; has a primary brain malignancy or metastases to the brain; has
clinically significant, uncontrolled cardiovascular disease; unless postmenopausal
(females) or surgically sterile; is unwilling to abstain from sexual intercourse
or employ highly effective contraception from the first dose of study drug and
for at least 6 weeks after the last dose of study drug; pregnant or breastfeeding;
hypersensitivity to avapritinib or to any of the excipients; unwilling or unable to
comply with the study procedures or requirements; and participation in another
interventional study.
Trial design and treatment. PATHFINDER (ClinicalTrials.gov identifier no.
NCT03580655) is an ongoing, international, multicenter, open-label, single-arm,
phase 2 registrational trial conducted in North America and Europe. Avapritinib
was administered at a starting dose of 200 mg QD in 28-day cycles until
progression, intolerance, withdrawal by the investigator or patient or death. Dose
modification to as low as 25 mg QD was allowed as per prespecified criteria. Dose
increases to 300 mg QD were allowed for lack of efficacy and dose interruptions for
platelet counts <50 × 109 l–1 were required, although platelet transfusion and growth
factor support were allowed on trial.
Previous cytoreductive therapy or investigational agents were permitted if
received up to 14 days before the screening bone marrow sample or up to 28 days
(cladribine, interferon alpha, pegylated interferon or any antibody therapy) before
the screening marrow biopsy. Medications, including palliative and supportive care
for disease-related symptoms, were permitted during the study and may include
the following classes of agents: histamine receptor H1 and H2 blockers; proton
pump inhibitors; osteoclast inhibitors (that is, bisphosphonates); leukotriene
receptor antagonists; corticosteroids (not exceeding 20 mg d–1 of prednisone or
equivalent, and dose must be stable for ≥14 days before C1D8); cromolyn sodium
and other mast cell stabilizers; and omalizumab.
Trial outcomes and assessments. The primary endpoint was optimal ORR as per
mIWG–MRT–ECNM criteria (Supplementary Table 2). Modifications to the IWG–
MRT–ECNM criteria were previously described7,13. Responses as per mIWG–
MRT–ECNM criteria were adjudicated by the Study Steering Committee based on
data from every trial visit, and required confirmation of ≥12 weeks. Bone marrow
samples were assessed by central pathology, and serum tryptase and KIT D816V
VAF in the blood were analyzed by central laboratory.
The primary analysis was originally planned after 63 patients in cohort 1 had
received at least ten cycles of therapy but, due to the high efficacy observed in the
EXPLORER trial, an interim analysis was introduced early in the PATHFINDER
trial, to be triggered when 32 patients in cohort 1 (interim analysis efficacy
population) had sufficient follow-up to be adjudicated for response as per mIWG–
MRT–ECNM criteria.
The key secondary endpoint was mean change from baseline in
patient-reported TSS of the AdvSM–SAF, a validated measure to assess treatment
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benefit in AdvSM patients24,25. Other secondary endpoints included time to
response (time from the start of treatment to the response according to mIWG–
MRT–ECNM criteria); duration of response (DOR; time from first documented
response to the date of the first documented disease progression/loss of response
or death due to any cause, whichever occurred first); PFS (time from the start
of treatment to the date of the first documented disease progression as per
mIWG–MRT–ECNM criteria or death due to any cause, whichever occurred
first); OS (time from the start of treatment to the date of death); and changes in
mast cell burden, safety and QoL using EORTC–QLQ–C30. Additional planned
secondary endpoints not reported in this manuscript included pharmacokinetics of
avapritinib and morphological response based on the Pure Pathological Response
criteria7,26.
Response according to mIWG–MRT–ECNM criteria was assessed at
C1D15, C2D1, C3D1, C7D1 and every six cycles thereafter, 12 weeks after
documentation of CR or PR, 4 weeks after progressive disease of the AdvSM
and/or AHN components and at the end of therapy if discontinued for a reason
other than progressive disease or initiation of alternative cytoreductive therapy.
Patient-reported outcomes (AdvSM–SAF, PGIS and EORTC–QLQ–C30) were
collected at each visit through cycle 17 and at the end of therapy (if before or at
cycle 17).
All patients were followed for safety (until 30 days after treatment
discontinuation) and for long-term survival every 3 months. Safety assessments
included determination of ECOG performance status, clinical laboratory testing,
vital signs, electrocardiograms, brain imaging (magnetic resonance imaging or
computerized tomography scan) and physical examinations. Treatment-emergent
AEs were defined as any AE that occurred between the first dose of avapritinib
through 30 days after the last dose of avapritinib, and were graded according to
National Cancer Institute Common Terminology Criteria for AEs, v.5.0.
Statistical analysis. The null hypothesis ORR of 28% versus the alternative
hypothesis, ORR of 50%, a one-sided type I error rate of 0.025 and a sample size of
approximately 63 patients in cohort 1 were determined to have 93.5% power using
the exact one-sample binomial test. The null hypothesis, ORR of 28%, was based
on ORR as per IWG–MRT–ECNM criteria for midostaurin19. The data cutoff date
for this interim analysis was 23 June 2020, and was performed when 32 patients
in cohort 1 had received six cycles of treatment and at least two postbaseline bone
marrow assessments or had an end-of-study assessment at any timepoint. In the
interim analysis, the null hypothesis was rejected if one-sided P < 0.00625. In
the case of failure of the interim analysis, the final analysis would be tested at a
one-sided alpha level of 0.02178. Two-sided 95% confidence intervals were based
on the exact binomial distribution (Clopper–Pearson method). Time-to-event
outcomes (DOR, PFS and OS) were determined using the Kaplan–Meier method,
and estimates were computed using Greenwood’s formula. Summary statistics
are presented for time to response. Maximum percentage baseline reduction in
clinicopathological measures of response (bone marrow mast cells, serum tryptase,
KIT D816V VAF and spleen volume) was based on patients with both baseline
(last observation before the date of the first dose of avapritinib, including pre-dose
assessments on this date) and at least one baseline assessment. The mean change
from baseline AdvSM–SAF TSS to C11D1 was tested against the null hypothesis
of ≥0. If one-sided, one-sample t-test P < 0.025, the null hypothesis was rejected.
Summary statistics and change from baseline are presented for PGIS and QoL
assessment by EORTC–QLQ–C30.
All safety analyses, QoL outcomes and secondary analyses were evaluated in
the safety population, comprising all enrolled patients. All statistical analyses were
conducted using SAS v.9.4 or higher.
Trial oversight and review. The trial was designed by the sponsor (Blueprint
Medicines Corporation) and trial investigators. The full protocol was approved by
the institutional review board (IRB) or independent ethics committee (IEC) of each
participating center: St Michael’s Hospital Research Ethics Board, Toronto, Canada;
East of England – Cambridge South Research Ethics Committee, Nottingham, UK;
University of Pennsylvania Office of Regulatory Affairs, PA, USA; Dana-Farber
Cancer Institute, Office for Human Research Studies, MA, USA; University of
Utah IRB, UT, USA; University of Michigan Medical School Institutional Review
Board, MI, USA; MD Anderson Cancer Center, Office of Protocol Research, TX,
USA; Stanford University, Research Compliance Office, CA, USA; Columbia
University Medical Center IRB, NY, USA; Western IRB, WA, USA; Rush University
Medical Center IRB, IL, USA; Washington University, Human Research Protocol
Office, MO, USA; Roswell Park IRB, NY, USA; Region Syddanmark, Vejle,
Denmark; Comité de protection des personnes Sud Est 1, Saint-Étienne, France;
Ethikkommission II der Universität Heidelberg, Medizinische Fakultät, Mannheim,
Germany; Medical Ethics Review Board, Groningen, the Netherlands; Comitato
Etico Campania Sud – ASL; Napoli 3 Sud, Italy; Comitato Etico Area Vasta Centro,
Florence, Italy; CEIC Hospital Universitari Pare Tau Ii – Oficina de Recerca,
Barcelona, Spain; REK SØR/ØST, Oslo, Norway; and Independent Bioethics
Committee for Scientific Research at the Medical University of Gdansk, Gdansk,
Poland. The trial was conducted in accordance with the Declaration of Helsinki,
International Conference on Harmonisation guidelines for Good Clinical Practice
and local regulations. All patients provided written informed consent. Participants
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were not compensated, except for reimbursement of reasonable travel expenses.
Each local IRB/IEC was notified based on local regulations (where required by
the IRB/IEC) of all serious, unexpected adverse drug reactions involving risk to
human patients. The sponsor and authors jointly collected and analyzed the data.
All authors had access to all data, reviewed and provided critical input to the
manuscript and made the decision to submit it for publication. All authors vouch
for the validity of the trial results and adherence to the protocol.
Reporting Summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.

Data availability

The anonymized derived data from this trial that underlie the results reported in
this article will be made available, beginning 12 months and ending 5 years after
this article’s publication, to any investigators who sign a data access agreement and
provide a methodologically sound proposal to medinfo@blueprintmedicines.com.
The trial protocol will also be made available, as will a data fields dictionary.
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Extended Data Fig. 1 | See next page for caption.
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Extended Data Fig. 1 | Patient Disposition. *Cohort 1: Patients with AdvSM and ≥1 mIWG-MRT-ECNM criteria for evaluable disease (have severe and
quantifiable organ damage (an evaluable C-finding) or have MCL (regardless of C-findings)) as confirmed by the SSC. Twenty patients in Cohort 1 were
not included in the interim analysis efficacy population due to lack of sufficient follow-up. †Patients with AdvSM who were not considered eligible for an
adjudicated response and were confirmed centrally to have ASM or SM-AHN, but were lacking an evaluable C-finding as determined by the SSC. ‡No
patient discontinued from treatment due to lost to follow-up, protocol deviation, pregnancy, investigator decision, non-compliance, sponsor decision,
or other reason. AdvSM, advanced systemic mastocytosis; AHN, associated hematologic neoplasm; AML, acute myeloid leukemia; ASM, aggressive
systemic mastocytosis; MCL, mast cell leukemia; mIWG-MRT-ECNM, modified International Working Group-Myeloproliferative Neoplasms Research and
Treatment and European Competence Network on Mastocytosis; SM-AHN, systemic mastocytosis with an associated hematologic neoplasm; SSC, study
steering committee; WHO, World Health Organization.
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Extended Data Fig. 2 | Prior Anti-Neoplastic Therapies (Interim Analysis Efficacy Population, n = 32). Table shows details of prior therapies received by
patients that ended on or before the first dose date of avapritinib.
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Extended Data Fig. 3 | Baseline Characteristics. Baseline characteristics including for patients not included in the interim analysis (n = 30). AdvSM,
advanced systemic mastocytosis; ASM, aggressive systemic mastocytosis; ddPCR, droplet digital polymerase chain reaction; ECOG, Eastern Cooperative
Oncology Group; MCL, mast cell leukemia; mIWG-MRT-ECNM, modified International Working Group-Myeloproliferative Neoplasms Research and
Treatment and European Competence Network on Mastocytosis; SM-AHN, systemic mastocytosis with associated hematologic neoplasm.
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Extended Data Fig. 4 | Response by mIWG-MRT-ECNM C-Findings (Interim Analysis Efficacy Population, n = 32). *Definitions of C-findings per
mIWG-MRT-ECNM and criteria for measuring clinical improvement are presented in Supplementary Table 1 and Supplementary Table 2. †Percentages are
based on the number of patients with C-finding at baseline. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase;
mIWG-MRT-ECNM, modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network
on Mastocytosis; ORR, overall response rate; ULN, upper limit of normal.
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Extended Data Fig. 5 | Change from Baseline in Clinicopathological Measures of Disease Burden. a, Peripheral blood absolute monocyte count in
patients with SM-CMML. b, Peripheral blood absolute eosinophil count in patients with baseline eosinophilia. SM-CMML, systemic mastocytosis with
chronic myelomonocytic leukemia.
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Extended Data Fig. 6 | Adverse Events Leading to Dose Modifications. *Pooled terms. †Patient reported to have increased bleeding propensity with
subcutaneous hematoma. AE, adverse event.
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